Is ACHC a good stock to buy? We came across a bullish thesis on Acadia Healthcare Company, Inc. on Valueinvestorsclub.com by ppsm920. In this article, we will summarize the bulls’ thesis on ACHC. Acadia Healthcare Company, Inc.’s share was trading at $23.73 as of March 17th. ACHC’s trailing and forward P/E were 19.82 and 12.44 respectively according to Yahoo Finance.
Countries with Lowest Abortion Rates in the World in 2018
Photographee.eu/Shutterstock.com
Acadia Healthcare (ACHC) represents a compelling turnaround opportunity in the U.S. behavioral health sector, an industry characterized by strong long-term supply-demand dynamics, high barriers to entry, and persistent psychiatric bed shortages. Following the sale of its UK business in 2021, Acadia deleveraged and focused exclusively on the U.S., growing patient volumes post-Covid and expanding aggressively with thousands of new beds.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
However, a combination of aggressive expansion, large legal settlements, and a management reset under CEO Chris Hunter, including front-loading liabilities and reserves into guidance, caused severe investor pessimism, with the stock down more than 80% from its 2024 peak. Despite headline risks, Acadia operates 278 facilities with 12,500 beds across four care levels—acute inpatient psychiatric hospitals, specialty treatment, comprehensive outpatient centers, and residential long-term care—serving critical, underserved needs amplified by rising mental health issues and opioid addiction.
The company’s growth has been capital-intensive, but with a clear shift toward free cash flow generation, lower capex, and focus on high-ROIC bed additions to existing facilities, operational efficiency is set to improve substantially. Normalization of labor costs and reduced startup losses could add $500–550 million to cash flow over a short period, while ongoing efforts to divest non-core assets may…
..
